Ergoteles’s ARS Pharmaceuticals SPRY Stock Holding History

Ergoteles’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-74,544	Closed	-$394K	–	1858
2022 Q3	$394K	Sell	74,544 -21,756	-23%	-$107K	0.01%	858
2022 Q2	$408K	Buy	+96,300	New	+$336K	0.01%	933

Other funds holding SPRY

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ergoteles's SPRY Position: Q4 2022 in Review

Ergoteles sold out of ARS Pharmaceuticals (SPRY) in Q4 2022, closing a stake of 74,544 shares — an estimated $394K sold.

Ergoteles first reported a position in SPRY in Q2 2022 and held it in 2 quarters. The position peaked at $408K in Q2 2022. 73 funds tracked by Wall St. Rank hold SPRY as of Q4 2022.

Ergoteles reported no remaining ARS Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Ergoteles sold 74,544 ARS Pharmaceuticals shares in Q4 2022, an estimated $394K.
Ergoteles first reported a position in ARS Pharmaceuticals in Q2 2022 and held it in 2 quarters.
Ergoteles's ARS Pharmaceuticals position peaked at $408K in Q2 2022.
73 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.